Global Automated Insulin Delivery System Market Size Likely to Grow at a CAGR of 10.5% By 2035

The market size of the global automated insulin delivery system will be estimated at USD 989 million in 2025 and is expected to grow between USD 1093 million in 2026 and about USD 2684 million by 2035 with a current CAGR of 10.5% during the period of 2026 to 2035.

Automated Insulin Delivery System Market Revenue and Trends

An Automated Insulin Delivery, or AID system, is a cutting-edge technology in diabetes management that will regulate, without human intervention, the infusion of insulin to persons with diabetes taking insulin. It connects 3 vital parts together, namely a continuous glucose monitoring (CGM) sensor that keeps constant check on the glucose level, an insulin pump that administers insulin, and a control algorithm that interprets glucose data and intermittently alters the insulin dose accordingly. With the AID systems maintaining a constant reaction to the glucose fluctuations, it will not be necessary to do the manual insulin adjustments so often; it will be easier to keep the blood glucose within the desired range, and the chances of hypoglycemia and hyperglycemia will be reduced. These systems/gadgets are commonly called hybrid or fully closed-loop systems (or "artificial pancreases"), and their ultimate goal is to make diabetes care easier, improve glycemic control, and improve the quality of life for the patient by offering insulin therapy that is more precise, personalized, and responsive.

The automated insulin delivery system market is being driven by technological advancements in diabetes care, shift toward personalized and automated diabetes management, growing awareness and adoption among patients, healthcare infrastructure and reimbursement expansion, and a focus on hybrid and fully closed-loop systems.

What are the Factors That Have a Significant Contribution to the Growth of the Automated Insulin Delivery System Market?

Technology wise the AID system market is claimed mainly to be focused on Hybrid and Fully Closed-Loop (FCL) systems, as they are the most complicated and advanced simultaneously in terms of the evolution of insulin therapy. The systems aim at nothing else than that. The systems are also the reason for this automation-based development.

Of course, along the lines of automatic insulin delivery, hybrid closed-loop technology has been marked out as the most common. The continuous process of glucose monitoring and delivery of insulin (mostly long-acting and corrective doses) via adjustments made in real time according to glucose level monitoring takes place in these automatic systems relying on CGM data. Still, the patients have to perform some tasks, for example, notifying the device of their meal time or the amount of carbs they will consume, so the system can predict the glucose rise after the meal. The strength of the hybrid system is that it can be controlled through automation that allows the user to control the degree of automation. It is almost complete elimination of glycemic fluctuations, reduction of nighttime hypoglycemia risk to a safe level, and easing daily management burden all at once. Quick regulatory approval and user-friendliness in clinical practice have been some factors contributing to their current status as the largest revenue-generating segment in the market.

To the contrary, fully closed-loop (FCL) systems have already taken the place of other automated diabetes care solutions and hence are the main topic of current developments and research investments. The main aim of those systems is to operate nearly entirely without any user involvement and to automatically deliver basal as well as bolus insulin while doing so without announcing meals or making manual adjustments. FCL systems are based on intelligent predictive algorithms, AI, and continuous learning models that can forecast glucose fluctuations by taking into consideration the current data, historical patterns, physical activity, and body responses. Thus, the insulin delivery through fully closed-loop systems is done in such a way as to prevent hypoglycemia and increase time-in-range, and at the same time, the daily management of diabetes becomes much easier.

Segment Insight

By Age Group

The geriatric segment is growing at a significant rate over the projected period. Management of blood sugar levels in elderly patients can be further complicated by the natural aging process, multiple health issues at the same time, and the fact that these patients are more likely to experience fluctuations of blood sugar levels—both high and low. Insulin treatment can be very hard and sometimes life-threatening for older adults due to possible miscalculations in the doses, unnoticed oozing of low blood leading to hospitalization, brain aging, and other serious health issues.

One of the greatest achievements in this field is Continuous Glucose Monitoring (CGM) combined with advanced dosing algorithms, which have been able to decrease the incidence of both hypoglycemia and glycemic variability as the patient’s insulin is continuously modulated or delivered based on real-time glucose data. This feature is an advantage for elderly patients who might find it difficult to undergo regular monitoring of their glucose levels and complicated calculations of their dosages.

Regional Insights

The automated insulin delivery system market has been dominated by North America. The growing technical advancement in the area and rising product launches offer a potential opportunity for market growth. Furthermore, the growing geriatric population drives the market expansion.

Besides, the Asia Pacific market has the highest rate of growth in the automated insulin delivery system market. The growing investment in healthcare infrastructure and increasing investment of international players in the area.

Report Scope

Recent Developments

• In April 2025, Medtronic plc, the company that is leading the healthcare technology sector globally, announced that it has submitted 510(k) requests to the U.S. Food and Drug Administration (FDA) in order to obtain clearance for an interoperable pump. The FDA approval for this pump would render it possible to pair it with a continuous glucose monitoring (CGM) sensor employing Abbott’s cutting-edge CGM platform. The submissions included a 510(k) request for the MiniMed™ 780G pump that was identified as an alternate controller enabled (ACE) insulin pump and a different 510(k) request for the SmartGuard™ algorithm that was identified as an interoperable automated glycemic controller (iAGC). (Source: https://news.medtronic.com/2025-04-24-Medtronic-advances-Abbott-CGM-partnership-with-FDA-submission-of-interoperable-insulin-pump)

List of the prominent players in the Automated Insulin Delivery System Market:

• F. Hoffmann-La Roche Ltd

• Tandem Diabetes Care Inc.

• Insulet Corporation

• Medtronic plc

• Beta Bionics Inc.

• Bigfoot Biomedical Inc.

• Diabeloop SAS

• Ypsomed AG

• Sooil Development Co. Ltd.

• DreaMed Diabetes Ltd.

• Sequel Med Tech LLC

• Abbott

• Medtrum Technologies Inc.

• Dexcom Inc.

• Others

The Automated Insulin Delivery System Market is segmented as follows:

By Product

• Predictive Low Glucose Suspend (PLGS) System

• Fully Closed Loop (FCL) System

• Hybrid Closed Loop (HCL)/Advanced Hybrid Closed Loop (AHCL) System

By Diabetes Type

• Type 1 Diabetes

• Type 2 Diabetes

By Age Group

• Pediatric

• Geriatric

• Adult

By End User

• Hospitals and Clinics

• Homecare Settings

• Others

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America